

## Planning Committee Member

The following Planning Committee members have relevant financial relationship(s) with ineligible companies to disclose.

- Maria Dall'Era, MD: AstraZeneca (Terminated): 2; Aurinia (Ongoing): 2; Biogen (Ongoing): 2; GlaxoSmithKlein(GSK) (Ongoing): 2; Janssen (Ongoing): 2; Pfizer (Ongoing): 2
- Peter Merkel, MD, MPH: AbbVie (Ongoing): 2, 5; AstraZeneca (Ongoing): 2, 5; Boehringer-Ingelheim (Ongoing): 2, 5; Bristol Myers Squibb (Ongoing): 2, 5; ChemoCentryx (Ongoing): 2, 5; CSL Behring (Ongoing): 2; Dynacure (Ongoing): 2; EMDSerono (Ongoing): 2; Forbuis (Ongoing): 2, 5; Genentech/Roche (Ongoing): 2, 5; Genzyme/Sanofi (Ongoing): 2, 5; Glaxo Smith Kline (Ongoing): 2, 5; InflaRx (Ongoing): 2, 5; Janssen (Ongoing): 2; Kiniksa (Ongoing): 2; Kyverna (Ongoing): 2; Magenta (Ongoing): 2; MiroBio (Ongoing): 2; Neutrolis (Ongoing): 2; Novartis (Ongoing): 2; Pfizer (Ongoing): 2; Sparrow (Ongoing): 2; Takeda (Ongoing): 2, 5; Talaris (Ongoing): 2; UpToDate (Ongoing): 9
- Joel Block, MD: Bioventus (Terminated): 2; CTI Clinical Trials (Terminated): 4; Focus Medical Communications (Terminated): 6; GlaxoSmithKlein(GSK) (Ongoing): 2; Global Academy for Medical Education (Terminated): 6; KAI Research Inc. (Ongoing): 4

## Faculty

The following Faculty members have no relevant financial relationship(s) with ineligible companies to disclose.

- Ronald Butendieck, Jr. MD
- Peter Grayson, MD, MSc
- Tiffany Hsu, MD, PhD
- Gale McCarty, MD, FACP, FACR
- John Pixley, MD, FACP, FACR
- Jeffrey Sparks, MD, MSc
- Karin Teague

The following Faculty members have relevant financial relationship(s) with ineligible companies to disclose.

- Rohit Aggarwal, MD, MS: Alexion (Ongoing): 2; Argenx (Ongoing): 2; Astra Zeneca (Ongoing): 2; Boehringer Ingelheim (BI) (Ongoing): 2; Bristol-Myers Squibb(BMS) (Ongoing): 2, 5; Corbus (Ongoing): 2; CSL Behring (Ongoing): 1, 2; EMD Serono (Ongoing): 2, 5; Genentech (Ongoing): 5; Janssen (Ongoing): 2; Kezar (Ongoing): 2; Kyverna (Ongoing): 2; Mallinckrodt (Ongoing): 1, 5; Octapharma (Ongoing): 1, 2; Orphazyme (Ongoing): 1; Pfizer (Ongoing): 2; Q32 (Ongoing): 2, 5
- Francesco Boin, MD: Boehringer-Ingelheim (Terminated: Ended 11-8-2021): 1, 6
- Kristin Gowin, MD: AbbVie/Abbott (Ongoing): 1, 6; Amgen (Ongoing): 1, 6
- Anne-Marie Malfait, MD, PhD : 23andMe (Terminated): 2; AKP (Terminated): 2; Eli Lilly (Terminated): 2; Galapagos (Terminated): 5; GSK (Ongoing): 5; Pfizer (Terminated): 2, 6; Vizuri (Terminated): 2
- Clyde Markowitz, MD: Alexian (Terminated): 2; Banner Life Sciences (Terminated): 2; Biogen (Ongoing): 2; Bristol-Myers Squibb(BMS) (Terminated): 2; EMD Biogen (Terminated): 2; Genentech/Roche (Terminated): 2; Genzyme/Sanofi (Terminated): 2; Janssen (Terminated): 2; Novartis (Terminated): 2; Teva (Terminated): 2; TG Therapeutics (Terminated): 2; Their Healthcare (Terminated): 2
- Joseph Merola, MD, MSc: AbbVie (Ongoing): 1, 2, 6; Amgen (Ongoing): 1, 2, 6; Biogen IDEC (Ongoing): 1, 2, 6; Eli Lilly (Ongoing): 1, 2, 6; Janssen Pharmaceuticals (Ongoing):

1, 2, 6, 6; LEO Pharma (Ongoing): 1, 2; Novartis (Ongoing): 1, 2, 6, 6; Pfizer (Ongoing): 1, 2, 6

- Christopher Ritchlin, MD, MPH: EqRX (Ongoing): 2; MoonLake (Ongoing): 2; Solarea (Ongoing): 2
- Michael Weinblatt, MD: chemocentryx (Ongoing): 2; eqrx (Ongoing): 2; genosco (Ongoing): 2; johnson & johnson (Ongoing): 2; kaledio (Ongoing): 2; kiniksa (Ongoing): 2; Lycera (Terminated: Ended 2019): 2, 11; Regeneron Pharmaceuticals (Terminated: Ended 2019): 5; Rpharma (Ongoing): 2; Samsung (Terminated: Ended 2019): 2; scirhom (Ongoing): 2

\*All of the relevant financial relationships listed for these individuals have been mitigated.